Cytokinetics Inc (Cytokinetics) discovers, develops and commercializes muscle activators and inhibitors for the treatment of muscle function disorder in cardiovascular and neuromuscular diseases. The company operates through one reportable segment. Its product pipeline consists of Omecamtiv Mecarbil, a cardiac muscle myosin activator in Phase III clinical trials for the treatment of heart failure with reduced ejection fraction (HFrEF); Aficamten (CK-274), an oral, small molecule cardiac myosin inhibitor in Phase III trials intended to reduce hypercontractility associated with hypertrophic cardiomyopathy (HCM); CK-136 (formerly AMG 594), a novel oral, small molecule cardiac troponin activator in Phase I for heart failure and other diseases; Reldesemtiv, a fast skeletal muscle troponin activator (FSTA) in Phase III for the treatment of muscle weakness, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA); CK-601, a next-generation FSTA in Preclinical Phase for the treatment of pathogenesis of neuromuscular and non-neuromuscular etiology. It is also developing additional skeletal muscle activators and muscle biology-directed products, which are in the research phase.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on the development of drug candidates for the treatment of muscle function disorder. It conducts muscle contractility research through its cardiac muscle contractility and skeletal muscle contractility program. Its cardiac muscle contractility program focuses on cardiac sarcomere, a basic unit of muscle contraction in the heart and the skeletal muscle contractility program focuses on the activation of the skeletal sarcomere, the basic unit of skeletal muscle contraction. It utilizes the knowledge and expertise gained through continuous exploration and development of cardiac sarcomere activators. In FY2022, the company incurred expenses of US$240.8 million on its R&D activities. Through research collaborations with Amgen and Astellas, Cytokinetics advances its muscle biology programs. The company intends to advance its business by seeking patent protection for the technologies, inventions and improvements. As of December 31, 2022, the company owned or licensed 73 issued US patents, over 650 issued patents in various countries and over 430 additional pending US and foreign patent applications.